产品名称
兔抗BRAF (V600E)单克隆抗体, recombinant, expressed in HEK 293 cells, clone RM8, purified immunoglobulin
recombinant
expressed in HEK 293 cells
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
RM8, monoclonal
recombinant monoclonal
form
buffered aqueous glycerol solution
species reactivity
human
concentration
~1 mg/mL
technique(s)
ELISA: 0.5-2 μg/mL
immunoblotting: 0.5-2 μg/mL
immunocytochemistry: 0.5-5 μg/mL
immunohistochemistry: 0.5-5 μg/mL
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... BRAF(673)
Biochem/physiol Actions
BRAF（B-Raf 原癌基因）参与细胞生长的直接信号传导。它通过在皮肤黑色素瘤、甲状腺癌和结肠癌等各种肿瘤中启动丝裂原活化蛋白激酶 (MAPK) 途径，诱导肿瘤生长。
该抗体与BRAF V600E突变体反应。与野生型BRAF无交叉反应。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
Features and Benefits
请完全放心地评估我们的抗体。如果抗体在您的研究中无效，我们将全额退款或换货。了解更多。
General description
BRAF（B-Raf 原癌基因）是一种丝氨酸-苏氨酸激酶，编码 B-Raf 蛋白。它位于人类染色体7q34上。
Immunogen
对应于BRAF V600E突变体的肽
Physical form
溶于含有50％甘油、1％BSA和0.09％叠氮化钠的磷酸盐缓冲盐水中。
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
常规特殊物品
此项目有
Xuhong Wang et al.
Oncology letters, 18(1), 927-935 (2019-07-11)
Keratin 19 (KRT19) is a type I cytokeratin that serves an important role in multiple types of cancer; however, little is known regarding its role in thyroid cancer. Therefore, the aim of the current study was to investigate the role
The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
Hannan EJ, et al.
Medicine, 96(48), e8404-e8404 (2017)
Daniel Delev et al.
Scientific reports, 10(1), 96-96 (2020-01-11)
Long-term epilepsy-associated tumors (LEATs) represent mostly benign brain tumors associated with drug-resistant epilepsy. The aim of the study was to investigate the specific transcriptional signatures of those tumors and characterize their underlying oncogenic drivers. A cluster analysis of 65 transcriptome
Maria Russi et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 180, 106311-106311 (2022-10-24)
Two clinically approved anticancer drugs targeting BRAF in melanoma patients - dabrafenib (DAB) and vemurafenib (VEM) - have been successfully encapsulated into nanomicelles formed upon self-assembly of an amphiphilic dendrimer AD based on two C18 aliphatic chains and a G2
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Shinozaki E, et al.
British Journal of Cancer, 117(10), 1450-1450 (2017)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持